CBLL
Ceribell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$27.47
−2.84%Research · Sep 2, 2026
CeriBell (CBLL): Clarity Readings Linked to 3.6x Discharge Risk
CeriBell's Q2 2026 call cited a study linking Clarity's seizure-burden readings to discharge outcomes, but revenue tied to the finding remains undisclosed.
Research · Aug 25, 2026
EEG Diagnostics Consolidates Rapid and Conventional Testing Into One System
Ceribell says FDA-cleared hardware lets one system do both rapid bedside EEG screening and the formal study, merging two hospital purchases into one from 2027.